Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Chronic Myelogenous Leukemia
NCT00129740Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2005
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Participants With Complete Molecular Response (Molecular CR) at 12 months. Started Jun 2005; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00129740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129740.